3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
10
Breast
4
Gastrointestinal
3
Thoracic
2
Sarcoma
2
Lymphoid
2
Gynecologic
2
Genitourinary
2
Dermatologic
2
Conditions
Carcinoma, Non-Small-Cell Lung
86
Lung Neoplasms
32
Small Cell Lung Carcinoma
18
Melanoma
17
Mesothelioma
13
Neoplasms
11
Colorectal Neoplasms
9
Carcinoma, Renal Cell
9
Squamous Cell Carcinoma of Head and Neck
7
Neoplasm Metastasis
7
Mesothelioma, Malignant
7
Carcinoma, Transitional Cell
7
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Urinary Bladder Neoplasms
5
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Liver Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Hepatocellular
5
Uterine Cervical Neoplasms
4
Stomach Neoplasms
4
Kidney Neoplasms
4
Brain Neoplasms
4
Carcinoma, Merkel Cell
3
Skin Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Interventions
pembrolizumab
34
Cisplatin
12
Nivolumab
10
atezolizumab
9
Docetaxel
9
Carboplatin
9
Paclitaxel
8
Cetuximab
8
Gemcitabine
7
Blood Specimen Collection
7
Radiotherapy
6
Fluorouracil
6
Drug Therapy
6
cemiplimab
5
Pemetrexed
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Standard of Care
4
Cyclophosphamide
4
spartalizumab
3
epacadostat
3
Surveys and Questionnaires
3
Oncolytic Virotherapy
3
Nicotine
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
Interleukin-2
3
Filgrastim
3
Bupropion
3
Bortezomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Ipilimumab
×
Thoracic
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled